Show/Hide Menu

Corporate Governance

We at MorphoSys believe the essence of good Corporate Governance involves efficient cooperation between a company’s Management and Supervisory Board, respect for the shareholders’ interests, as well as openness and transparency of corporate communication. Moreover, we feel strong corporate governance is an integral part of the MorphoSys corporate value system. As such, the company believes that adherence to high Corporate Governance standards will ultimately increase shareholder value.

 

MorphoSys ensures compliance with the laws and rules of conduct, especially through the use of a Group-wide Code of Conduct, as well as through supplementary internal guidelines. MorphoSys’s “Code of Conduct” sets out the fundamental principles and key policies and practices for behavior in business. The Code serves as a valuable tool for employees and management staff particularly in business, legal, and ethical situations of conflict.

In addition, the Code of Conduct strengthens transparency and consistent management principles as well as the strengthening the trust in the Company of the financial markets, business partners, employees, and the public. Compliance with the Code of Conduct is carefully monitored. The Group-wide implementation of the Code is accompanied by the Code of Conduct Committee.

Statement on Corporate Governance pursuant to sec. 289a of the German Commercial Code (HGB) for the 2015 financial year

In the Statement on Corporate Governance under Sec. 289a HGB, the Management Board and the Supervisory Board report on corporate governance. In addition to the annual Declaration of Conformity in accordance with Sec. 161 of the Stock Corporation Act (AktG), the Statement on Corporate Governance also includes relevant information on corporate governance practices and other aspects of corporate governance, including a description of the working practices of the Management Board and Supervisory Board..

Declaration of Conformity with the German Corporate Governance Code (the "Code") of the Management Board and the Supervisory Board of MorphoSys AG

The Management Board and Supervisory Board of MorphoSys AG declare the following under Sec. 161 of the German Stock Corporation Act:

  1. Since the last Declaration of Conformity on December 5, 2014, MorphoSys AG has complied with the recommendations of the “Government Commission on the German Corporate Governance Code” dated June 24, 2014 and the version from May 5, 2015 with the following exceptions:
    • a) There is no cap on the overall or individual variable remuneration components of Management Board members’ remuneration (see Item 4.2.3 Para. 2 sentence 6 of the Code). Based on the Supervisory Board’s existing limitations for the Management Board’s variable remuneration components and their annual allocation, the Supervisory Board does not believe that an additional cap is required.
    • b) Until July 21, 2015, the Supervisory Board refrained from fully applying the recommendations in Item 5.4.1 Paras. 2 and 3 sentence 1 of the Code. According to Item 5.4.1 Para 2, the Supervisory Board shall specify certain objectives regarding the Board’s composition that provides for an appropriate level of female participation. Recommendations made by the Supervisory Board to the responsible election bodies shall take these objectives into account in accordance with Item 5.4.1 Para. 3 sentence 1. The Supervisory Board has established concrete objectives for its composition and has thereby resolved to strive for adequate female representation. An exact quota of women was not specified because qualification and not gender should be the deciding criteria in appointing members of the Supervisory Board. As of July 22, 2015, the recommendations in Item 5.4.1 Paras. 2 and 3 sentence 1 of the Code have been fully applied because on this date a corresponding quota was established.
  2. MorphoSys will continue to comply with the recommendations of the “Government Commission on the German Corporate Governance Code” in the version dated May 5, 2015 with the exceptions described under Item 1a.

Martinsried/Planegg, 3 December 2015

MorphoSys AG

For the Management Board For the Supervisory Board
Dr. Simon E. Moroney
Chief Executive Officer
Dr. Gerald Möller
Chairman

 

Relevant Information on Corporate Governance Practices

MorphoSys ensures compliance with laws and rules of conduct through the Group-wide application of the following documents: the Code of Conduct, the Compliance Handbook and supplementary internal guidelines.

MorphoSys’s Code of Conduct sets out the fundamental principles and key policies and practices for business behavior. The code is a valuable tool for employees and executives, particularly in business, legal and ethical situations of conflict. It reinforces the principles of transparent and sound management and fosters trust in the Company from the financial markets, business partners, employees and the public. Compliance with the Code of Conduct is carefully monitored. The Group-wide application of the Code is overseen by a Code of Conduct Committee, and the Code itself is routinely reviewed and updated when necessary. The Code of Conduct can be downloaded from the Company’s website under Media and Investors – Corporate Governance.

The Compliance Handbook describes MorphoSys’s compliance management system and is intended to ensure compliance with all legal regulations as well as set out high ethical standards that apply to both the management and all employees. The Management Board has overall responsibility for the compliance management system and is required to report regularly to the Audit Committee and the Supervisory Board. In carrying out its compliance responsibility, the Management Board has assigned the relevant tasks to various offices at MorphoSys.

The Compliance Officer monitors the communication between the individual compliance posts within MorphoSys and makes adjustments to the system as needed in consultation with the Management Board. The Compliance Officer also routinely reports all relevant developments in the Company’s compliance system to the Chief Executive Officer.

The Compliance Officer is supported by a Compliance Committee that meets at regular intervals to discuss compliance issues. This committee serves as a liaison between the various departments dealing with compliance issues and facilitates the identification and discussion of all the compliance posts’ relevant issues. This is the basis upon which the Compliance Officer periodically verifies adherence to the compliance management system and MorphoSys’s compliance status. 

Composition of the Management Board and the
Supervisory Board

 

The Management Board

The Management Board of MorphoSys AG consists of the Chief Executive Officer and three other members. A schedule of responsibilities defines the different areas of responsibility as follows:

  • Dr. Simon Moroney, Chief Executive Officer, responsible for Strategy and Planning; Compliance and Quality Assurance; Internal Audit; Human Resources; Business Development & Portfolio Management; Legal; the coordination of individual areas of the Management Board; and representation of the Management Board to the Supervisory Board.
  • Jens Holstein, Chief Financial Officer, responsible for Accounting and Taxes; Controlling; Corporate Finance & Corporate Development; Risk Management; IT; Technical Operations; Procurement & Logistics; Corporate Communications and Investor Relations; and Environmental Social Governance (ESG).
  • Dr. Arndt Schottelius, Chief Development Officer, responsible for Preclinical Development; Clinical Research; Clinical Operations; Drug Safety & Pharmacovigilance; Regulatory Affairs; and Project Management.
  • Dr. Marlies Sproll, Chief Scientific Officer responsible for Development Partnerships & Technology Development; Target Molecule & Antibody Research; Protein Chemistry; Alliance Management; and Intellectual Property.

Biographies of the Management Board members

Supervisory Board

As of 31 December 2015, the MorphoSys AG Supervisory Board consisted of six members who oversee and advise the Management Board. The current Supervisory Board consists of professionally qualified members who represent MorphoSys AG shareholders. Dr. Gerald Möller, acting Chairman of the Supervisory Board, coordinates the Board’s activities, chairs the Supervisory Board meetings and represents the interests of the Supervisory Board externally. All Supervisory Board members are independent, as defined in the German Corporate Governance Code, and have many years of experience in the biotechnology and pharmaceutical industries. The members are duly elected by the shareholders during the Annual General Meeting. The Chairperson of the Supervisory Board is not a former member of MorphoSys AG’s Management Board. The terms of office of all six Supervisory Board members ended with the conclusion of the 2015 Annual General Meeting and, therefore, six Supervisory Board members were either elected or reelected to the Supervisory Board during the 2015 Annual General Meeting.

The members of the Supervisory Board and its committees are listed in the table below.

 

Composition of the Supervisory Board until Termination of the 2015 Annual General meeting

  Initial
Appointment
End of
Period 1
Audit
Committee
Remuneration and Nomination
Committee
Science
and Technology
Committee
Dr. Gerald Möller 1999 2015   C  
Dr. Geoffrey Vernon (FE) 1999 2015 M    
Dr. Walter Blättler 2007 2015     C
Dr. Daniel Camus (FE) 2002 2015 C    
Dr. Marc Cluzel 2012 2015   M M
Karin Eastham (FE) 2012 2015 M M  

1 Period ends with termination of Annual General Meeting 2015 

FE=Independent Financial Expert     C=Chairman     M=Member

 

Composition of the Supervisory Board Since Termination of the 2015 Annual General meeting

  Initial
Appointment
End of
Period
Audit
Committee
Remuneration and Nomination
Committee
Science
and Technology
Committee
Dr. Gerald Möller 1999 2018   M  
Dr. Frank Morich 2015 2017     M
Karin Eastham (FE) 2012 2018 M C  
Klaus Kühn (FE) 2015 2017 C    
Dr. Marc Cluzel 2012 2018   M C
Wendy Johnson 2015 2017 M   M

FE=Independent Financial Expert     C=Chairman     M=Member

 

Working Practices of the Management Board and Supervisory Board

To ensure good corporate governance, a guiding principle of the cooperation between the Management Board and Supervisory Board at MorphoSys AG is the open, comprehensive and regular communication of information. The dual board system prescribed by the German Stock Corporation Act clearly differentiates between a company’s management and supervision. The responsibility of both Boards is clearly stipulated by the legislator and the Boards’ bylaws and Articles of Association. The stated objective of MorphoSys AG’s Management Board and Supervisory Board is to sustainably increase Company value. The Boards work closely together to make decisions and take actions for the Company’s benefit.

Management Board members have their own area of responsibility defined in the schedule of responsibilities and regularly report to their Management Board colleagues. Cooperation among Management Board members is governed by the bylaws. The Supervisory Board ratifies both the schedule of responsibilities and the bylaws. Management Board meetings are typically held weekly and chaired by the Chief Executive Officer. During these meetings, resolutions are passed concerning dealings and transactions that, under the bylaws, require the approval of the entire Management Board. At least half of the Management Board’s members must be present to pass a resolution. Management Board resolutions are passed by a simple majority and, in the event of a tied vote, the Chief Executive Officer’s vote decides. For material events, each Management Board or Supervisory Board member can call an extraordinary meeting of the entire Management Board. Management Board resolutions can also be passed outside of meetings by an agreement made orally,  y telephone or in writing (also by e-mail). A written protocol is completed for each meeting of the full Management Board and is submitted for approval to the full Management Board and for signature to the chief executive officer at the following meeting.

Management Board strategy workshops are also held in which the Group-wide strategic objectives are developed and prioritized.

The Management Board promptly and comprehensively informs the Supervisory Board in writing and at Supervisory Board meetings about planning, business development, the Group’s position, risk management and other compliance issues. Extraordinary meetings of  the Supervisory Board are also called for material events. The Management Board involves the Supervisory Board in the strategy, planning and all fundamental Company issues. In addition to routine Supervisory Board meetings, a strategy meeting takes place between  the Management Board and Supervisory Board once annually to discuss MorphoSys’s strategic direction. The Management Board’s bylaws specify that material business transactions require the approval of the Supervisory Board. Detailed information on the cooperation  of the Management Board and Supervisory Board and important items of discussion during the 2015 financial year can be found in the Report of the Supervisory Board.

The Supervisory Board holds a minimum of two meetings per calendar half-year and at least six meetings per full calendar year. The Supervisory Board has supplemented the Articles of Association with rules of procedure that apply to its duties: The Chairperson of the supervisory Board coordinates the activities of the Supervisory Board, chairs the Supervisory Board meetings and represents the interests of the Supervisory Board externally. The Supervisory Board typically passes its resolutions in meetings, but resolutions may also be  passed outside of meetings in writing (also by e-mail), by telephone or video conference.

The Supervisory Board has a quorum when at least two-thirds of its members (including either the Chairperson or Deputy Chairperson of the Supervisory Board) take part in the vote. Resolutions of the Supervisory Board are passed with a simple majority unless the law  rescribes otherwise. In the event of a tied vote, the Chairperson of the Supervisory Board’s vote decides.

Protocols are completed for Supervisory Board meetings, and resolutions passed outside of meetings. A copy of the Supervisory Board’s protocol is made available to all Supervisory Board members. The Supervisory Board conducts an efficiency evaluation regularly in  accordance with the recommendation in Item 5.6 of the Code.

Composition and Working Practices of the Management Board's and Supervisory Board's Committees

The Management Board has not formed any committees.

The Supervisory Board has three committees: the Audit Committee, the Remuneration and Nomination Committee, and the Science and Technology Committee. The members of the three committees formed by the Supervisory Board are professionally qualified..

Audit Committee

The main task of the Audit Committee is to support the Supervisory Board in fulfilling its supervisory duties with respect to the accuracy of the annual and consolidated financial statements, the activities of the auditor and internal control functions, such as risk management, compliance and internal auditing. The Audit Committee submits a recommendation to the Supervisory Board for the election at the Annual General Meeting of an independent auditor. The members of the Audit Committee until May 8, 2015, were Dr. Daniel Camus (Chairman), Dr. Geoffrey Vernon and Karin Eastham, who all fulfill the prerequisite of being independent financial experts. The members of the Audit Committee as of May 8, 2015, were Klaus Kühn (Chairman), Karin Eastham and Wendy Johnson. Klaus Kühn and Karin Eastham fulfill the prerequisite of being independent financial experts.

Remuneration & Nomination Committee

The Remuneration and Nomination Committee is responsible for preparing and reviewing the Management Board’s compensation system annually before its final approval. When necessary, the Committee searches for suitable candidates to appoint to the Management Board and Supervisory Board and submits appointment proposals to the Supervisory Board. The Committee also prepares the contracts made with Management Board members. The members of the Remuneration and Nomination Committee are Dr. Gerald Möller (Chairman until May 8, 2015), Dr. Marc Cluzel and Ms. Karin Eastham (Chairperson as of May 8, 2015).

Science & Technology Committee

The Science and Technology Committee advises the Supervisory Board on matters concerning proprietary drug and technology development and prepares the relevant Supervisory Board resolutions. The members of the Science and Technology Committee until May 8, 2015 were Dr. Walter Blättler (Chairman) and Dr. Marc Cluzel. As of May 8, 2015, the members of the Science and Technology Committee are Dr. Marc Cluzel (Chairman), Dr. Frank Morich and Ms. Wendy Johnson.

Declaration of Conformity with regard to the German Corporate Governance Code

Declaration of Conformity of the Management and Supervisory Board of MorphoSys AG with regard to the German Corporate Governance Code (“Code”)

The Management Board and the Supervisory Board of MorphoSys AG declare pursuant to Section 161 of the German Stock Corporation Act:

  1. From December 5, 2014, the date of its most recent Declaration of Conformity, MorphoSys AG has complied – with the exceptions described below – with the recommendations of the “Government Commission on the German Corporate Governance Code” in the Code version dated June 24, 2014 and the Code version dated May 5, 2015:
  • The amount of compensation of the Management Board members does not provide for a cap, neither overall nor for individual compensation components (see item 4.2.3 para. 2 sentence 6 of the Code). Against the background of already existing means of the Supervisory Board to cap variable compensation components of the Management Board members as well as the annual allocation of such variable components, the Supervisory Board considers an additional cap relating to the overall and individual compensation components as unnecessary.
  • Until July 21, 2015 the Supervisory Board had abstained from complying in full with the recommendations of item 5.4.1 para. 2 and para. 3 sentence 1 of the Code. Pursuant to item 5.4.1 para. 2, the Supervisory Board shall specify concrete objectives regarding its composition, which in particular shall stipulate an appropriate degree of female representation. According to item 5.4.1 para. 3 sentence 1, proposals by the Supervisory Board to the competent election bodies shall take these objectives into account. The Supervisory Board had specified concrete objectives regarding its composition and thereby also decided to aim for an adequate representation of women on the Supervisory Board. A concrete quota for female members of the Supervisory Board had however not been defined since the individual qualification and not the gender of Supervisory Board candidates should be the decisive criteria for the composition of the Supervisory Board. As of July 22, 2015 the recommendations of item 5.4.1 para. 2 and para. 3 sentence 1 of the Code are fully applied since the Supervisory Board resolved a respective quota on that day.
  1.  MorphoSys AG will continue to comply – with the exception described above under item 1.a. – with the recommendations of the “Government Commission on the German Corporate Governance Code” in the Code version dated May 5, 2015.

 

Martinsried/Planegg, December 3, 2015
MorphoSys AG

 

For the Management Board For the Supervisory Board
Dr. Simon E. Moroney
Chief Executive Officer
Dr. Gerald Möller
Chairman of the Supervisory Board

 

Archive

Compensation

Remuneration of the Management Board

The Management Board’s remuneration system is intended to provide an incentive for performance-oriented and sustainable corporate management. Therefore, the aggregate remuneration of the Management Board members consists of different components: fixed components, an annual cash bonus based on the achievement of individual and corporate targets (short-term incentive – STI), a variable compensation component with a long-term incentive (long-term incentive – LTI) and other remuneration components. The variable remuneration component with long-term incentive consists of a performance share plan and convertible bond programs from prior years. Management Board members also receive fringe benefits in the form of non-cash benefits, mainly the use of a company car and the payment of insurance premiums. All remuneration packages are reviewed annually for their scope and appropriateness by the Remuneration and Nomination Committee and compared to the results of an annual management board remuneration analysis. The amount of compensation paid to Management Board members highly depends on their individual areas of responsibility, their personal achievement of goals, the Company’s economic situation and success and the Company’s business prospects versus its competition. All decisions concerning adjustments to the remuneration package are made by the entire Supervisory Board. The Management Board’s remuneration and index- linked pension scheme were last adjusted in July 2015.

For a list of remuneration relating to individual Management Board members, divided into fixed components as well as short- and long-term incentivizing components, see the Remuneration Report as part of the Annual Report 2015.

 

Remuneration of the Supervisory Board

The remuneration of Supervisory Board members is governed by the Company’s Articles of Association and a corresponding Annual General Meeting resolution on Supervisory Board remuneration. In the 2015 financial year, Supervisory Board members received fixed compensation, attendance fees and expense allowances for their participation in Supervisory Board and committee meetings. Since 2014, each Supervisory Board member has received annual fixed compensation (€ 85,400 for Chairpersons, € 51,240 for Deputy Chairpersons and € 34,160 for all other members) for their membership of the Supervisory Board. The Chairperson receives € 4,000 for each Supervisory Board meeting chaired and the other members receive € 2,000 for each Supervisory Board meeting attended. For committee work, the committee Chairperson receives € 12,000 and other committee members each receive € 6,000. Committee members also receive € 1,200 for their participation in a committee meeting. Compensation is paid quarterly on a pro-rated basis. A resolution of the Annual General Meeting on May 8, 2015 made two changes to the rules governing Supervisory Board remuneration: Participation in a Supervisory Board meeting by telephone or video conference results in a 50 % reduction in compensation for meeting participation and, in certain cases, a fixed expense allowance is granted for travel time when a meeting is personally attended. Therefore, Supervisory Board members residing outside of Europe who personally take part in a Supervisory Board or committee meeting are entitled to a fixed expense allowance of € 2,000 (plus any sales tax due) for additional travel time in addition to attendance fees and reimbursed expenses.

Supervisory Board members are also reimbursed for travel expenses and value-added taxes (VAT) on their compensation.

In the 2015 financial year, Supervisory Board members received a total of € 529,270 (2014: € 514,480) excluding the reimbursement of travel expenses. This amount consists of fixed compensation and attendance fees for participating in Supervisory Board and committee meetings.

No loans were granted to Supervisory Board members by the Company.

For a list of remuneration relating to individual Supervisory Board members, see the Remuneration Report as part of the Annual Report 2015.

Managers' Transactions (formerly known as "Directors' Dealings")

Pursuant to Art. 19 para. 5 subparagraph 1, sentence 1 of the European Market Abuse Regulation (“MAR”) the Members of the Management and Supervisory Boards of MorphoSys AG, as well as persons closely associated with them , are legally bound to report trading in MorphoSys stock to the German Federal Financial Supervisory Authority (BaFin). Every transaction conducted on their own account relating to the shares or debt instruments of MorphoSys or to derivatives or other financial instruments linked thereto must be reported.

All transactions have to be published unless the total value of these tradings executed by such person within one calendar year does not exceed EUR 5,000.

Notes:
Participants in the MorphoSys stock option and/or convertible bonds programs who choose to “exercise and sell” receive the difference between the so-called exercise price (price determined at the time of issuing the options) and the Xetra closing price of the MorphoSys stock on the day of exercise, as a taxable income.

All reported transactions of MorphoSys AG are published via GlobeNewswire.

Declared Security Transactions

Date Name and Function Transaction Type, Number & Security Date, Place, Price & Transaction Volume
June 9, 2016 Jens Holstein, CFO Sale of 9,997 MorphoSys AG shares; the shares sold derive from the Long-Term-Incentive (LTI-) Program 2012 of MorphoSys; from overall 12,997 shares out of this program, Mr. Holstein holds 3,000 shares. June 7, 2016
XETRA, EUR 47.017
EUR 470,028.949
May 17, 2016 Dr. Marlies Sproll, CSO Sale of 3,100 MorphoSys AG shares; the shares sold derive from the Long-Term-Incentive (LTI-) Program 2012 of MorphoSys; from overall 12,997 shares out of this program, Dr. Sproll holds 6,760 shares. May 13, 2016
XETRA, EUR 45.1284
EUR 139,898.04
May 17, 2016 Dr. Marlies Sproll, CSO Sale of 3,137 MorphoSys AG shares; the shares sold derive from the Long-Term-Incentive (LTI-) Program 2012 of MorphoSys; from overall 12,997 shares out of this program, Dr. Sproll holds 6,760 shares. May 12, 2016
XETRA, EUR 43.8891
EUR 137,680.11
January 13, 2016 Dr. Arndt Schottelius, CDO Purchase of 400 MorphoSys AG shares January 12, 2016
XETRA, EUR 48.55
EUR 19,420.00
December 17, 2015 Dr. Simon Moroney, CEO Purchase: 18,800 convertible bonds were converted into MorphoSys AG shares. Dr. Moroney is holding the shares received. December 16, 2015
off-exchange, EUR 16.79
EUR 315,252.00
December 17, 2015 Dr. Marlies Sproll, CSO Sale: 9,500 convertible bonds were converted into MorphoSys AG shares and subsequently sold. December 16, 2015
XETRA, EUR 56.1934
EUR 533,837.30
December 17, 2015 Dr. Marlies Sproll, CSO Purchase: 14,000 convertible bonds were converted into MorphoSys AG shares. Dr. Sproll is holding the shares received. December 15, 2015
off-exchange, EUR 16.79
EUR 235,060.00
December 17, 2015 Dr. Marlies Sproll, CSO Sale: 9,500 convertible bonds were converted into MorphoSys AG shares and subsequently sold. December 15, 2015
XETRA, EUR 56.0253
EUR 532,240.35
June 8, 2015 Dr. Arndt Schottelius, CDO Sale of 5,392 MorphoSys AG shares; the shares were granted within MorphoSys's long term incentive (LTI) program 2011 after a four-year waiting period. The shares were subsequently sold. June 3, 2015
XETRA, EUR 66.1085
EUR 356,457.03
June 8, 2015 Dr. Arndt Schottelius, CDO Sale of 5,370 MorphoSys AG shares; the shares were granted within MorphoSys's long term incentive (LTI) program 2011 after a four-year waiting period. The shares were subsequently sold. June 3, 2015
XETRA, EUR 65.6735
EUR 352,666.70
June 8, 2015 Dr. Arndt Schottelius, CDO Sale of 5,370 MorphoSys AG shares; the shares were granted within MorphoSys's long term incentive (LTI) program 2011 after a four-year waiting period. The shares were subsequently sold. June 2, 2015
XETRA, EUR 66.0633
EUR 354,759.92
June 8, 2015 Dr. Marlies Sproll, CSO Sale of 2,667 MorphoSys AG shares; the shares were granted within MorphoSys's long term incentive (LTI) program 2011 after a four-year waiting period. The shares were subsequently sold. June 4, 2015
XETRA, EUR 65.6343
EUR 175,046.68
June 8, 2015 Dr. Marlies Sproll, CSO Sale of 2,667 MorphoSys AG shares; the shares were granted within MorphoSys's long term incentive (LTI) program 2011 after a four-year waiting period. The shares were subsequently sold. June 3, 2015
XETRA, EUR 65.8605
EUR 175,649.95
June 8, 2015 Dr. Marlies Sproll, CSO Sale of 2,666 MorphoSys AG shares; the shares were granted within MorphoSys's long term incentive (LTI) program 2011 after a four-year waiting period. The shares were subsequently sold. June 2, 2015
XETRA, EUR 65.6746
EUR 175,088.48
June 8, 2015 Jens Holstein, CFO Sale of 3,381 MorphoSys AG shares; the shares were granted within MorphoSys's long term incentive (LTI) program 2011 after a four-year waiting period. The shares were subsequently sold. June 4, 2015
XETRA, EUR 65.6343
EUR 221,909.57
June 8, 2015 Jens Holstein, CFO Sale of 5,381 MorphoSys AG shares; the shares were granted within MorphoSys's long term incentive (LTI) program 2011 after a four-year waiting period. The shares were subsequently sold. June 3, 2015
XETRA, EUR 65.8605
EUR 354,395.35
June 8, 2015 Jens Holstein, CFO Sale of 5,370 MorphoSys AG shares; the shares were granted within MorphoSys's long term incentive (LTI) program 2011 after a four-year waiting period. The shares were subsequently sold. June 2, 2015
XETRA, EUR 65.6746
EUR 352,672.60
May 13, 2015 Dr. Frank Morich, Deputy Chairman of the Supervisory Board Purchase of 1,000 MorphoSys AG shares May 12, 2015
Frankfurt, EUR 63.51
EUR 63,510.00
Apr 2, 2015 Dr. Gerald Möller,
Chairman of the Supervisory Board
Purchase of 2,000 MorphoSys AG shares March 27, 2015
Frankfurt, EUR 56.70
EUR 113,400.00
Apr 2, 2015 Karin Eastham, Member of the Supervisory Board Purchase of 1,000 MorphoSys AG shares March 27, 2015
OTC, USD 61.8129
USD 61,812.90

 

 

Holdings of the Boards as of June 30, 2016

  Shares Convertible Bonds Performance Shares
Management Board
Dr. Simon Moroney 514,214 88,386 37,220
Jens Holstein 7,000 90,537 25,134
Dr. Arndt Schottelius 2,400 60,537 38,131
Dr. Marlies Sproll 57,512 60,537 25,134
Supervisory Board
Dr. Gerald Möller (Chairman) 11,000 0 0
Dr. Frank Morich 1,000 0 0
Dr. Marc Cluzel 500 0 0
Karin Eastham 2,000 0 0
Wendy Johnson 500 0 0
Klaus Kühn 0 0 0

For a detailed description of the stock option schemes and convertible bonds programs for the employees of MorphoSys Group, we refer to the latest financial reports.